The prevalence of NCDs (non-communicable diseases) has increased exponentially in South Asia in recent years; India being the largest contributor[1,2]. Mortality and morbidity due to NCDs is much higher in low-income and middle-income countries, as compared to wealthier nations [3].
In 2018, Annual Health Survey and in 2020, the District-Level Household Survey reported diabetes and hypertension in 100242/1320555 (7.6%) and 350273/1320555 (26.5%) respectively [4,5]; with faster conversion to diabetes from prediabetes in Asian Indians [6,7]. Hypercholesterolemia and obesity have been reported in 241/739 (68.5%) and 347/739 (32.6%) of the population respectively. In other studies, low HDL cholesterol was seen in 1010/1227 (82.3%) of the Asian Indians. A series of five cross-sectional epidemiological studies from Jaipur in India showed a secular trend of increase in BMI, hypertension and total and non-HDL cholesterol over a 20-year period [8-16]. However, many of these studies presented results from secondary analysis of various survey datas which did not specifically address NCDs and others did not include a truly representative population of India.
The Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study, [17] the largest survey on diabetes and other metabolic NCDs conducted in 2023 quantified the prevalence of NCDs and their interstate and interregional variations. It reported a much increased prevalence of metabolic NCDs in India. The study reports on the prevalence of diabetes and prediabetes in different states of India using robust sampling and diagnostic methods and therefore helps in assessing the present status of the diabetes epidemic and its likely future trajectory. However, this study did not include disorders of uric acid and thyroid disorders which have also become a significant source of morbidity and mortality.
We planned this multicentric study to quantify the self reported diabetes, hypertension, obesity, hyperuricemia, heart disease and thyroid disorders and compare it with the actual the existing prevalence data.
Study design & sampling method:
This was a multicentric cross-sectional questionnaire-based survey which was conducted from various centres in India after getting approval from ethics committee. Convenience sampling of participants was done from various hospitals or clinics in India from West, North, South and Northeast zones. (According to the literature, convenience sampling can be used to draw generalizations about certain sample features and is an option for researchers who are short on time, labor, etc).
Inclusion & exclusion criteria: All adults aged 18 years and above coming to OPD or admitted in wards and of sound mind, with effective coordination and communication skills were included. Those stricken with acute complications such as infection, ketoacidosis, hyperosmolar hyperglycemia, etc. or suffering from malignant diseases or in the advanced stage of other serious diseases or serious complications of diabetes, such as diabetic nephropathy, fundus lesions, diabetic foot, etc, were excluded. Those incapable of caring for themselves due to mental illnesses or severe cognitive dysfunction or with underlying severe hearing disorders and/or speech impairments or with cognitive impairments affecting questionnaire comprehension or who declined to participate were also excluded.
Questionnaire development and adminisration:
The questionnaire consisted of simple questions on demographic information like age and gender and self-reported medical history like diabetes, hypertension, heart disease, lipid disorder, hyperuricemia etc. (Appendix 1) The questionnaire was developed by healthcare professionals and research team and was validated by a panel of experts including endocrinologist, cardiologist, epidemiologist and public health researcher. The questionnaire was distributed through various channels such as: Local health clinics, community centre and social media platforms. All efforts were taken to ensure anonymity and confidentiality of participant responses.
Data Collection:
The questionnaire was sent as google forms to the participant’s phone through a sharing app and they were provided clear instructions on how to complete the questionnaire. Confirmation for consent to proceed with the survey was taken from the patients and then they were asked for the language that they understood well. The questions were asked in the same language with which the patient was comfortable. The questionnaire was filled by the patients if they were literate enough to understand the questions and used phones or the attending doctors (they will fill the participant’s responses) if the patient couldn’t use the phone. The survey responses were kept anonymous. Contact details were stored separately from survey responses. The completed questionnaires were collected from participants and were checked for completeness and consistency of responses. The data so collected was entered into a secure electronic database for analysis. The data is described with descriptive statistics like mean and percentage.
Total 968 responses were received. Out of these, 80 (8%) were in 20 -30 years age group, 140 (14%) were in 30-40 years age group while 290 (29%), 310 (31%) and 180 (18%) belonged to the 40-50 years, 50-60 years and > 60 year age groups respectively.560 (56%) were males and 440 (44%) were females. (Table 1)
Table 1: Demographic characteristics of study population
|
Demographic characteristics |
N (%) |
|
20 -30 years |
77 (7.95%) |
|
30-40 years |
134 (13.84%) |
|
40-50 years |
281 (29.02%) |
|
50-60 years |
298 (30.78%) |
|
> 60 years |
178 (18.38%) |
|
Males |
544 (56.19%) |
|
Females |
424 (43.80%) |
Out of the total participants, most prevalent self reported metabolic disorder was obesity 403 (41.63%), followed by hypertension in 202 (20.87%) and dyslipidemia in 196 (20.25%). 60 (6.19%) reported to have heart disease, 82 (8.47%) reported to have hypothyroidism and 66 (6.82%) reported to have uric acid abnormality. 60 (6.19%)reported to be unaware of their metabolic status.(Table 2)
Table 2: Distribution of self reported metabolic disorders among the study participants
|
Metabolic disorder |
Yes |
No |
Don’t know |
|
Diabetes (n=968) |
143 (14.77%) |
808 (83.47%) |
17 (1.75%) |
|
Heart disease (n=968) |
60 (6.2%) |
877 (90.59%) |
31 (3.2%) |
|
Lipid Abnormalities (n=968) |
197 (20.35%) |
709 (73.24%) |
62 (6.40%) |
|
Hypertension (n=968) |
202 (20.87%) |
746 (77.07%) |
20 (2.07%) |
|
Thyroid disorders (n=968) |
82 (8.47%) |
847 (87.5%) |
39 (4.03%) |
|
Overweight/ Obese (n=968) |
403 (41.63%) |
565 (58.37%) |
- |
|
Uric acid Abnormality (n=968) |
66 (6.82%) |
858 (88.64%) |
44 (4.55%) |
On comparing the results with those of ICMR-INDIAB and other studies, it was observed that there was a huge difference in prevalence of self reported hypertension [202/968 (20.87 %)] and dyslipidaemia [196 (20.29%)] reported in this study and prevalence of detected hypertension (40.7%) and dyslipidemia (82.9%) respectively in other studies. Similarly, there was a large difference seen in thyroid and uric acid disorders reported in this study [82/968 (8.47%) and 66/968 (6.82%) respectively)] and other previous studies (28.6% and 20-25% respectively). The figures of obesity and diabetes were similar in the compared studies. (Table 3)
Table 3: Comparison of results with that of ICMR INDIAB study urban areas
|
Metabolic disorder |
Metabolic profiling study (2024), n=968 |
ICMR INDIAB study (2023) n = 57117 |
Other studies |
|
Diabetes |
143 (14.77 %) |
9367 (16.4 %) |
6.5 – 7.5% [8] |
|
Hypertension |
202 (20.87 %) |
23246 (40.7 %) |
25 – 30% [4] |
|
Obesity |
403 (41.63 %) |
22618 (39.6 %) |
>30% [9,17] |
|
Dyslipidemia |
197 (20.35 %) |
47349 (82.9 %) |
> 80% [14] |
|
Heart disease |
60 (6.2 %) |
Not reported |
7-8% [18] |
|
Thyroid disorders |
82 (8.47 %) |
Not reported |
28.6% [19] |
|
Uric acid abnormality |
66 (6.82 %) |
Not reported |
20-25% [20,21] |
This study quantifies the burden of self reported prevalence of metabolic disorders namely diabetes, hypertension, obesity, dyslipidemia, heart disease, thyroid disorders and uric acid abnormalities. Many other studies have addressed the same issue in past, however in most of these studies, either the participants did not represent the population, results were derived from surveys which did not primarily deal with NCDs or did not include thyroid or uric acid disorders.
An increasing trend in diabetes, hypertension and obesity was seen in previous studies [100 242 /1320555 (7.5%) to 9367/57117 (16.4%); 25-30% to 11588/33063 (40.7%) and 30% to 22618/57117 (39.6%) respectively] in last 4-5 years [4,8,17]. This study (2024) reported diabetes in 143 (14.77%) population, hypertension in 202 (20.87%) and obesity in 403 (41.63%) population. The ICMR-INDIAB study (2023) reported similar prevalence of diabetes and obesity [4272/31560 (16.4%) and 12135/32784 (39.6%) respectively] but it reported hypertension in 11588/33063 (40.7%) persons [17]. The difference seen may be because this study relied on self reported hypertension while the ICMR-INDIAB study relied on measured hypertension. [17] This may suggest that either the people were not aware of their hypertension or may be in denial of their hypertensive status. This also suggests that they were more aware and in acceptance of diabetes and obesity.
There was also a huge difference in dyslipidemia reported in this and the other recent studies [197/968 (20.35%) and 4493/5415 (82.9%) respectively] [13,14,17], which may be attributed to refusal to accept or to the fact that the higher proportion of rural population coming to urban areas for management may have been exposed to measurement of lipid profile as a part of referral for advanced investigation and management.
Various studies from 2016 to 2023 reported prevalence of heart disease, thyroid disorders and uric acid abnormalities to be 39091/390913 (10%), 13715 /97971 (20%) and 7582/29391 (25.8%) respectively[18-21]. This study observed self reported heart disease, thyroid disorders and uric acid abnormalities in 62/967(6.2%), 82/967(8.47%) and 66/967(6.82%) respectively. As with hypertension and dyslipidemia, the actual figures might be much more than observed as many would not have been reported due to ignorance of symptoms and lack of acceptance.
Thus, it appears that despite the substantial burden of metabolic disorders, a major proportion of the population who are suffering from metabolic disorders either do not know about the same or are in the stage of refusal. Such persons are least likely to take any measures for prophylaxis or early management leading to development of associated complications and deterioration of quality of health. Looking at this scenario, it becomes apparent that a mass awareness programme is urgently needed to reduce the probability of exponential increase in prevalence of metabolic disorders. This will also work towards reducing the morbidity and mortality, improving the quality of life of the general population and reducing the overall health expenses.
Small sample size considering the volume of the problem, addressing only one part of global population and it being questionnaire based depending upon the patients’ reporting are the limitations of the study, but this study addresses a comparatively ignored area of the problem, that is unawareness and denial. A larger study to understand these dynamics in different populations will help in formation of local policies to spread awareness, and acceptance to effectively manage and restrain further spread of the metabolic diseases.
A large proportion of population suffers from metabolic disorders but is either unaware or refuse to accept their metabolic status which results in lack of motivation to take precautions to avoid progression to debilitating complications. A mass awareness programme about metabolic disorders and their complications is needed to prevent the increasing prevalence of metabolic disorders turn into an epidemic.
None
[1] Institute for Health Metrics and Evaluation, Human Development Network, The World Bank. The global burden of disease: generating evidence, guiding policy—South Asia regional edition. Seattle, WA: IHME, 2013.
[2] Siegel KR, Patel SA, Ali MK, et al. Non-communicable diseases in South Asia: contemporary perspectives. Br Med Bull. 2014, 111: 31–44. 10.1093/bmb/ldu018
[3] Anjana RM, Mohan V, Rangarajan S, et al. Contrasting associations between diabetes and cardiovascular mortality rates in low-, middle-, and high-income countries: cohort study data from 143,567 individuals in 21 countries in the PURE Study. Diabetes Care. 2020, 43: 3094–101. 10.2337/dc20-0886
[4] Geldsetzer P, Manne-Goehler J, Theilmann M, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018, 178: 363–72. 10.1001/jamainternmed.2017.8094.
[5] Varghese JS, Anjana RM, Geldsetzer P, et al. Diabetes diagnosis, treatment, and control in India: results from a national survey of 1.65 million adults aged 18 years and older, 2019-2021. medRxiv. 2023. 10.1101/ 2023.02.06.23285544.
[6] Narayan KMV, Kanaya AM. Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. Diabetologia. 2020, 63: 1103–09. 10.1007/s00125-020-05132-5.
[7] Anjana RM, Shanthi Rani CS, Deepa M, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). Diabetes Care. 2015, 38: 1441–48. 10.2337/dc14-2814.
[8] Tandon N, Anjana RM, Mohan V, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018, 6: e1352–62. 10.1016/S2214-109X(18)30387-5.
[9] Jung L, De Neve JW, Chen S, et al. The interaction between district level development and individual-level socioeconomic gradients of cardiovascular disease risk factors in India: a cross-sectional study of 2.4 million adults. Soc Sci Med. 2019, 239: 112514. 10.1016/j.socscimed.2019.112514.
[10] Gupta R, Guptha S, Gupta VP, Agrawal A, Gaur K, Deedwania PC, et al. Twenty-year trends in cardiovascular risk factors in India and influence of educational status. Eur J Prev Cardiol. 2012, 19: 1258–71. 10.1177/1741826711424567.
[11] International Institute for Population Sciences (IIPS) and ICF. National Family Health Survey (NFHS-5), 2019–21: India: Volume I. Mumbai: IIPS, 2021. https://dhsprogram.com/pubs/ pdf/FR375/FR375.pdf.
[12] Unnikrishnan R, Gupta PK, Mohan V, et al. Diabetes in south Asians: phenotype, clinical presentation, and natural history. Curr Diab Rep. 2018, 18: 30-38. 10.1007/s11892-018-1002-8.
[13] Enas EA, Dharmarajan TS, Varkey B, et al. Consensus statement on the management of dyslipidemia in Indian subjects: a different perspective. Indian Heart J. 2015, 67: 95–102. 10.1016/j.ihj.2015.03.020.
[14] Bilen O, Kamal A, Virani SS. Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: current state and future directions. World J Cardiol. 2016, 8: 247–57. 10.4330/wjc.v8.i3.247.
[15] Karthikeyan G, Teo KK, Islam S, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol. 2009, 53: 244–53. 10.1016/j.jacc.2008.09.041.
[16] Gupta R, Sharma KK, Gupta A, et al. Persistent high prevalence of cardiovascular risk factors in the urban middle class in India: Jaipur Heart Watch-5. J Assoc Physicians India. 2012, 60: 11–16. PMID: 22799108
[17] Ranjit Mohan Anjana, Ranjit Unnikrishnan, Mohan Deepa et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023,11: 474–89. 10.1016/S2213-8587(23)00119-5.
[18] Gupta R, Mohan I, Narula J. Trends in Coronary Heart Disease Epidemiology in India. Ann Glob Health. 2016, 82(2):307-15. 1016/j.aogh.2016.04.002. PMID: 27372534.
[19] Yadav DK, Srivastava A, Saxena P, Singh R. Thyroid Dysfunction and its Significance in Heart Failure. J Assoc Physicians India. 2023, 71(1):1. PMID: 37116023.
[20] Billa G, Dargad R, Mehta A. Prevalence of Hyperuricemia in Indian Subjects attending Hyperuricemia Screening Programs-A Retrospective Study. J Assoc Physicians India. 2018,66 (4):43-6. PMID: 30347952.
[21] Patni B, Singh AN, Singh NK, et al. Prevalence of Hyperuricemia in Indian Population with Hypertension. J Assoc Physicians India. 2023, 71(10):45-48. 10.59556/japi.71.0364. PMID: 38716523.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications